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-Arrestins (arr) are multifunctional adaptor proteins that can act as scaffolds for G protein-coupled
receptor activation of mitogen-activated protein kinases (MAPK). Here, we identify the actin-binding and
scaffolding protein filamin A (FLNA) as a arr-binding partner using Son of sevenless recruitment system
screening, a classical yeast two-hybrid system, coimmunoprecipitation analyses, and direct binding in vitro. In
FLNA, the arr-binding site involves tandem repeat 22 in the carboxyl terminus. arr binds FLNA through
both its N- and C-terminal domains, indicating the presence of multiple binding sites. We demonstrate that
arr and FLNA act cooperatively to activate the MAPK extracellular signal-regulated kinase (ERK) down-
stream of activated muscarinic M1 (M1MR) and angiotensin II type 1a (AT1AR) receptors and provide
experimental evidence indicating that this phenomenon is due to the facilitation of arr-ERK2 complex
formation by FLNA. In Hep2 cells, stimulation of M1MR or AT1AR results in the colocalization of receptor,
arr, FLNA, and active ERK in membrane ruffles. Reduction of endogenous levels of arr or FLNA and a
catalytically inactive dominant negative MEK1, which prevents ERK activation, inhibit membrane ruffle
formation, indicating the functional requirement for arr, FLNA, and active ERK in this process. Our results
indicate that arr and FLNA cooperate to regulate ERK activation and actin cytoskeleton reorganization.
Cytoskeletal reorganization is fundamental for cell shape
change, signaling, locomotion, and many other important dy-
namic cellular processes. The MAPK JNK, p38, and ERK play
key roles in the regulation of cytoskeletal dynamics (21), as
many extracellular signals that promote a change in cell shape
converge at MAPK, which in turn phosphorylate downstream
targets involved in actin cytoskeleton regulation. For example,
ERK can phosphorylate myosin light chain kinase (27, 37),
calpain (18), focal adhesion kinase (22), and ribosomal S6
kinase (15), which all play important roles in cytoskeletal re-
organization and cell migration.
Initially appreciated for their roles in G protein-coupled
receptor desensitization and endocytosis, -arrestins are now
considered multifunctional adaptor molecules, with over 20
binding partners, including trafficking proteins, nonreceptor
tyrosine kinases, guanine nucleotide exchange factors, and
MAPK components, identified to date (28, 29). There exist two
isoforms of arr, arr1 and arr2. These share a high degree
of homology (80%) and several biological functions, such as
their abilities to bind to agonist-occupied GPCRs, preventing
G protein-mediated signal transduction, and to bridge recep-
tors with components of the clathrin-dependent endocytic ma-
chinery (clathrin and AP-2). With regard to MAPK, arr can
act as scaffolds for GPCR-mediated activation of ERK1/2 (12,
33), JNK3 (35), and p38 (44). arr bind multiple components
of MAPK cascades to promote efficient activation of MAPK,
additionally redirecting them to extranuclear compartments
(12, 33, 35). The arr-mediated cytoplasmic sequestration of
active ERK, for example, results in both direct and indirect
effects within the cell. First, by redirecting active ERK from the
nucleus to the cytoplasm, arr inhibits activation of the tran-
scription factor Elk-1 (45, 46), a nuclear ERK target, and
functionally results in a decrease in proliferation (12, 45). Sec-
ond, the targeting of active ERK to specific cytoplasmic com-
partments presumably permits the kinase to phosphorylate a
specific subset of substrates. Despite the increasing number of
observations indicating that both arr and MAPK are required
for GPCR-dependent chemotaxis and/or cell shape regulation
(16, 17, 23, 44), the specific cytoskeletal regulatory pathways
involved remain to be elucidated and likely implicate addi-
tional key arr partners.
The filamin family of actin-binding proteins are large scaf-
folding molecules that integrate cell signaling events and cell
shape change (43) and would be attractive candidates to pro-
vide a link between arr-mediated signaling events and cy-
toskeletal regulation. These proteins are located in the periph-
ery of the cytoplasm, where they cross-link actin filaments into
three-dimensional networks and link them to cellular mem-
branes. There are three isoforms of FLN, namely, FLNA,
FLNB, and FLNC; these share around 70% homology and are
structurally similar. FLNA and FLNB are widely expressed in
human tissues, whereas FLNC is expressed predominantly in
muscle (46). Structurally, FLNA is a 280-kDa dimer composed
of an amino-terminal actin-binding domain; 24 repeat regions,
each composed of around 96 amino acids; and two hinge re-
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gions that give the molecule flexibility. Dimerization occurs via
the carboxy-terminal repeat 24 of FLNA. Both the actin-bind-
ing and dimerization domains are required for the branching
of actin filaments. FLNA interacts with a number of proteins
with roles in signaling and cytoskeletal reorganization and is
regulated by phosphorylation. Of particular note is the fact
that FLNA binds to several members of the GPCR family,
including dopamine D2/D3 (30, 31), calcium-sensing receptor
(5, 20), and -opioid receptor (39), as well as other classes of
receptors, such as the insulin receptor (19). FLNA also inter-
acts with the Rho family GTPases Rho, Rac, Cdc42, and GTP-
bound RalA (38). The p21-activated kinase 1, a downstream
effector of Rac1 and Cdc42, binds and phosphorylates FLNA
and is reciprocally activated by FLNA in a two-way regulatory
interaction (47). Finally, like arr, FLNA has also been impli-
cated in MAPK signaling induced by a variety of extracellular
stimuli. Indeed, FLNA can interact with the MAPK kinases
MEK1 and MKK4 (34) and is phosphorylated by ribosomal S6
kinase (49), an ERK target.
Using a cytoplasmic yeast two-hybrid system (Sos recruit-
ment system) we identified FLNA as a arr-binding partner
and have assessed here its role in GPCR-induced arr-medi-
ated ERK activation and cytoskeletal rearrangement. Our data
indicate that FLNA and arr cooperate to orchestrate cell
shape change via a signaling pathway that involves ERK acti-
vation.
MATERIALS AND METHODS
Abbreviations. The following abbreviations are used in this paper: AT1AR,
angiotensin II type 1a receptor; arr, -arrestin(s); CaR, calcium-sensing recep-
tor; FLN, filamin; FLNA, filamin A; GPCR, G protein-coupled receptor;
Gal4AD, Gal4 activation domain; LexABD, LexA DNA binding domain;
M1MR, muscarinic M1 receptor; Sos, Son of sevenless; SRS, Sos recruitment
system; GEF, guanine nucleotide exchange factors; JNK, Jun N-terminal kinase;
ERK, extracellular signal-regulated kinase; MAPK, mitogen-activated protein
kinase(s); MAP2K, MAPK kinase(s); mGAP, mammalian GTPase-activating
protein; HA, hemagglutinin; Ura, uracil; GST, glutathione S-transferase; GFP,
green fluorescent protein; YFP, yellow fluorescent protein; IgG, immunoglobu-
lin G; ACh, acetylcholine; siRNA, small interfering RNA; RNAi, RNA inter-
ference; PBS, phosphate-buffered saline; P-ERK1/2, phospho-ERK1/2; SDS-
PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; and SEM,
standard error of the mean.
cDNA expression constructs. (i) Yeast two-hybrid expression vectors. The
plasmid pSosGly was generated by inserting an adaptor coding for five glycine
residues in frame with and 3 to the carboxy terminus of the hSos cDNA
sequence, using the NcoI and AatII sites contained in pSos (Stratagene), to
reduce structural interference between the two proteins in the chimera upon
expression. Subsequently, full-length arr2 (amino acids 1 to 410) was amplified
by PCR and introduced downstream of and in frame with the SosGly fusion by
use of ssHII and SalI sites to create pSosGlyarr2. A series of pSosGlyarr2
C-terminal truncations was created by introducing stop codons at various
places in the arr2 cDNA within pSosGlyarr2 by use of a QuikChange
mutagenesis kit (Stratagene). By use of this methodology, pSosGlyarr2C4
(coding for amino acids 1 to 392 of arr2), pSosGlyarr2C3 (amino acids 1 to
380), pSosGlyarr2C2 (amino acids 1 to 359), pSosGlyarr2C1 (amino acids
1 to 337), and pSosGlyarr2C (amino acids 1 to 316) were generated.
Plasmids for expression of FLNA(22-24), containing amino acids 2363 to 2647
of FLNA, fused to the Gal4AD or LexABD were constructed by excising
FLNA(22-24) from pMyr-FLNA(22-24) obtained in the SRS screen (see below)
by use of EcoRI and XhoI sites and insertion into EcoRI/XhoI sites of
pGAD-GE or EcoRI/SalI sites of pLex10, respectively. To generate arr1 and
arr2 fused to the Gal4AD, full-length arr were amplified by PCR and cloned
into pGAD-GE using XhoI/XbaI sites. Similarly, arr2 was amplified by PCR
and inserted into the SalI site of pLex10 to create a LexABD-arr2 hybrid.
pLex-Ras and pGAD-Raf have been described previously (42) and were kindly
provided by S. Benichou (Institut Cochin, Paris, France).
(ii) Bacterial expression vectors. To allow the production of a bacterial FLNA
fusion protein for use in pulldown experiments, pHis6-TAT-HA-FLNA(22-24)
was generated by cloning the EcoRI/XhoI fragment of FLNA(22-24) into
pTAT-HA (a kind gift from S. Dowdy, HHMI, Washington University School of
Medicine) between KpnI and XhoI restriction sites. arr cDNAs were amplified
by PCR and cloned into pGEX-5X-1 (Amersham) by use of PspAI/XhoI (for
arr1) or SalI/NotI (for arr2) sites to allow the production of GST-arr fusion
proteins.
(iii) Mammalian expression vectors. pMyc-FLNA(22-24) and pFLAG-FLNA
(22-24) were generated by excising FLNA(22-24) cDNA from pMyr-FLNA(22-
24) by use of EcoRI and XhoI sites and inserting it in frame to and downstream
of Myc and FLAG tags in pCMVTag3B and pCMVTag2B (Stratagene), respec-
tively, by use of the same sites. cDNAs corresponding to amino acids 2363 to
2554, 2363 to 2522, 2386 to 2647, and 2427 to 2647 of FLNA were amplified
by PCR and cloned between EcoRI and XhoI sites in pCMVTag3B to create
pMyc-FLNA(2363-2554), pMyc-FLNA(2363-2522), pMyc-FLNA(2386-2647),
and pMycFLNA(2427-2647), respectively. pMyc-FLNA(22-24) alanine-scan-
ning mutants 1 to 9 (see Fig. 4) were generated using a QuikChange mu-
tagenesis kit.
Full-length arr1 (amino acids 1 to 418) and full-length arr2 were amplified
by PCR; arr1 was cloned into pCMVTag2A and arr2 to pCMVTag3A by use
of EcoRV and SalI sites to generate pFLAG-arr1 and pMyc-arr2, respectively.
The N-terminal domain of arr2 (amino acids 1 to 185) and the C-terminal
domain of arr2 (amino acids 186 to 410) were amplified by PCR and cloned
either between the EcoRI and XhoI sites (for the N-terminal domain) or be-
tween the BamHI and SalI sites (for the C-terminal domain) of pCMVTag3B to
create pMyc-arr2N(1-185) and pMyc-arr2C(186-410), respectively. The integ-
rity of all constructs was verified by nucleotide sequencing (MWG or Institut
Cochin sequencing facility). Sequences of all primers used are available on
request.
pcDNA3.1-HA-M1MR was obtained from the Guthrie cDNA Resource Cen-
ter and pEYFP-tubulin from Clontech. The plasmids for pcDNA3.1-HA-
AT1AR, pCMV5-arr1, pcDNA1-AT1AR-DRY/AAY, and full-length pCMV-
FLNA expression plasmid were gifts of M. G. Caron, R. J. Lefkowitz (HHMI,
Duke University Medical Center), L. Hunyady (Semmelweis University, Buda-
pest, Hungary), and C. J. Loy (National University of Singapore, Singapore),
respectively. R. Seger (The Weizmann Institute of Science, Israel) provided the
pMEKK97A and pGFP-ERK2 constructs. parr2-FLAG has been described
previously (41).
SRS library screening. Library screening was performed sequentially. First,
cdc25H yeast cells (Stratagene) were cotransformed with pSosGlyarr2C1 bait
plasmid (containing amino acids 1 to 337 of arr2) and a plasmid (pYes2-GAP,
a kind gift of A. Aronheim, Rappaport Faculty of Medicine, Haifa, Israel)
containing mGAP to reduce Ras GTPase false positives obtained in the screen
(3). Subsequently, pSosGlyarr2C1/mGAP-containing cdc25H yeast cells were
transformed with a human thymus cDNA library fused to a myristylation signal
(Stratagene) under the control of the galactose-induced pGal1 promoter. Fol-
lowing library transformation, yeast cells were plated onto Leu/Ura/Trp agar
plates containing 2% galactose (to induce library expression) and 1% raffinose
and placed at 25°C for 40 h before being shifted to 37°C (nonpermissive tem-
perature). Clones that grew at 37°C after 5 to 7 days were scored as potential
arr interactors, and plasmid DNA was subsequently extracted and sequenced.
By use of this approach, approximately 1.5  106 clones were screened. To
determine the specificity of the interactions, prey plasmids were retransformed
into pSosGlyarr21/mGAP cdc25H yeast. Three days after transformation,
yeast cells growing at 25°C on Leu/Ura/Trp plates containing 2% glucose
were subsequently patched onto Leu/Ura/Trp plates containing either 2%
glucose or 2% galactose-1% raffinose and assessed for growth at 37°C 3 to 5 days
later. Clones that grew at 37°C in the presence of galactose (prey induced) but
not glucose (prey repressed) were considered bona fide interactors.
Classical yeast two-hybrid assay. The L40 yeast reporter strain containing a
LexA-inducible gene, HIS3, was cotransformed with pLexABD and pGal4AD
hybrid expression vectors and plated on selective medium. Transformants were
subsequently assayed for histidine auxotrophy as previously described (42).
Cell culture. COS and Hep2 cells were maintained in Dulbecco’s modified
Eagle medium supplemented with 10% fetal calf serum (GIBCO), penicillin, and
streptomycin (100 IU of penicillin and 100 g of streptomycin/ml; Sigma) at 37°C
in a humidified 5% CO2 atmosphere. Human A7 and M2 melanoma cells were
a generous gift of T. P. Stossel and Y. Ohta (Brigham and Women’s Hospital,
Harvard Medical School). The M2 melanoma cells are FLNA deficient. The A7
cell line was derived from M2 melanoma cells through the stable expression of a
plasmid encoding full-length FLNA (11). M2 and A7 cells were maintained in
minimal essential medium with Earle’s salt supplemented with 8% newborn calf
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serum, 2% fetal calf serum, penicillin, and streptomycin at 37°C in a humidified
5% CO2 atmosphere. In addition, A7 cells were subcultured in the presence of
0.5 mg/ml G418 (GIBCO) to maintain the presence of the FLNA-containing
plasmid.
Immunoprecipitation and immunoblotting. Approximately 3  106 COS cells
growing in 100-mm dishes were transiently cotransfected with 1 g FLAG
epitope-tagged arr or FLNA expression constructs using GENEJuice (Nova-
gen) and 1 g of plasmids encoding Myc fusion or wild-type proteins, as indi-
cated in the figure legends. Forty-eight hours posttransfection, cells were lysed in
1 ml of cold glycerol lysis buffer (50 mM Tris [pH 8.0], 150 mM NaCl, 2 mM
EDTA, 1% Triton X-100, 10% glycerol, 100 M Na3VO4, 1 mM NaF, supple-
mented with protease inhibitors) and clarified by centrifugation at 13,000  g for
20 min at 4°C. Immunoprecipitations were performed on 500 g of cell lysates by
use of 20 l of a 50% slurry of monoclonal M2 anti-FLAG-affinity agarose, with
constant agitation overnight at 4°C. Following incubation, immune complexes
were washed four times with lysis buffer, and immunoprecipitated proteins were
detected by Western blot analysis. Additionally, cell lysates (25 g) were sub-
jected to Western blot analysis to confirm expression of transfected constructs.
Coimmunoprecipitation experiments with full-length FLNA or endogenous pro-
teins were performed as described above with the following modifications. Cells
were lysed in 1 ml of lysis buffer 1 (50 mM Tris [pH 7.5], 150 mM NaCl, 1%
NP-40, 0.5% sodium deoxycholate, 100 M Na3VO4, 1 mM NaF, supplemented
with protease inhibitors) and clarified by centrifugation at 13,000  g for 20 min
at 4°C. Following immunoprecipitation, immune complexes were washed twice
with lysis buffer 1, twice in lysis buffer 2 (50 mM Tris [pH 7.5], 500 mM NaCl,
0.1% NP-40, 0.05% sodium deoxycholate), and twice in lysis buffer 3 (50 mM Tris
[pH 7.5], 0.1% NP-40, 0.05% sodium deoxycholate). Coimmunoprecipitation
experiments with FLAG-arr1, GFP-ERK2, and FLNA(22-24) were performed
as previously described (45).
Western blotting for FLAG fusion proteins was performed using rabbit poly-
clonal anti-FLAG antibody (Sigma) at a 1:1,000 dilution. Coprecipitated Myc
fusion, arr1, and full-length FLNA proteins were detected by use of rabbit
polyclonal anti-Myc (Santa Cruz) at a 1:1,000 dilution, anti-arr1 (a kind gift of
J. Benovic, University of Philadelphia) at a 1:1,000 dilution, and monoclonal
FLNA (Chemicon) antibodies at a 1:1,000 dilution, respectively. Horseradish
peroxidase-conjugated polyclonal donkey anti-rabbit or anti-mouse IgG was used
as a secondary antibody.
ERK activation experiments were performed essentially as previously de-
scribed (46). COS cells growing in six-well plates (approximately 3.5  105
cells/well) were transfected with plasmids encoding HA-M1MR, HA-AT1AR, or
AT1AR-DRY/AAY (250 ng/well) and GFP-ERK2 (125 ng/well) with or without
FLAG-arr1 or -2 (375 ng/well) and with or without Myc-FLNA(22-24) (125
ng/well). Following overnight serum starvation, cells were stimulated with either
100 M acetylcholine or 1 M angiotensin II for 5 min and subsequently lysed
in 300 l cold glycerol lysis buffer/well. To determine expression of transfected
proteins and phospho-ERK, aliquots of clarified whole-cell lysates (25 g) were
subjected to SDS-PAGE, transferred to nitrocellulose, and immunoblotted with
anti-ERK1/2 (Upstate) at a 1:20,000 dilution, anti-phospho-ERK1/2 (Cell Sig-
naling) at a 1:2,000 dilution, or anti-Myc and anti-FLAG rabbit polyclonal
antibodies as described above. Horseradish peroxidase-conjugated polyclonal
donkey anti-rabbit IgG was used a secondary antibody.
A7 and M2 cell lysates (30 g) were subjected to SDS-PAGE, transferred to
nitrocellulose, and probed with anti-FLNA mouse monoclonal antibody and
anti-arr (A2CT, a kind gift from Robert J. Lefkowitz, HHMI, Duke University
Medical Center) at a 1:5,000 dilution, anti-MEK1 (Cell Signaling) at a 1:1,000
dilution, and anti-ERK1/2 rabbit polyclonal antibodies. Horseradish peroxidase-
conjugated polyclonal donkey anti-rabbit or anti-mouse IgG was used as a sec-
ondary antibody. Blots were developed using either an ECL kit (Amersham) or
Supersignal chemiluminescence reagent (Pierce).
Immunofluorescence. A7 and M2 cells were seeded onto coverslips in six-well
plates and used for immunofluorescence 2 days later. Cells were fixed and
processed for fluorescence microscopy as previously described (40).
Hep2 cells were transfected and processed for immunofluorescence essentially
as previously detailed (25) with some modifications. Briefly, cells were grown to
60 to 70% confluence in 100-mm dishes (approximately 7  106 cells) prior to
transfection by electroporation in HEBS buffer (20 mM HEPES, 137 mM NaCl,
5 mM KCl, 0.7 mM Na2HPO4, 6 mM D-glucose) using two 450-V, 125-F pulses
(Gene Electropulser II; Bio-Rad) and 0.5 g of relevant cDNAs in the presence
or absence of 20 g of relevant siRNA. Forty-eight or 72 (for siRNA transfec-
tions) hours posttransfection, cells were treated as described in the figure leg-
ends. Following treatment, cells were fixed in 4% paraformaldehyde-PBS for 20
min at 4°C and quenched for 10 min in 0.27% NH4Cl-0.37% glycine in PBS at
room temperature. A 1% bovine serum albumin-0.2% saponin-PBS mixture was
subsequently used to block and permeabilize fixed cells. Primary antibody incu-
bations with rat anti-HA (3F10; Roche) or rabbit anti-arr (A2CT) at a 1:100
dilution, anti-MEK1 (Santa Cruz) at 1:250 dilution, or a mouse anti-FLNA at a
1:200 dilution were performed for 1 h at room temperature. Cells were subse-
quently washed with 1% bovine serum albumin-0.2% saponin-PBS and incu-
bated with Alexa Fluor donkey anti-rat (647), anti-rabbit (594), or anti-mouse
(488) immunoglobulin (Molecular Probes) at a 1:800 dilution for 45 min at room
temperature. After being washed, coverslips were mounted on slides in 90%
glycerol (Sigma)–3% N-propyl-galate (Sigma)–PBS. Where indicated, coverslips
were stained with Alexa Fluor 594 phalloidin (Molecular Probes) according to
the manufacturer’s instructions before mounting. Essentially the same protocol
was used for the detection of P-ERK1/2 in Hep2 cells with the following excep-
tion. A mouse anti-P-ERK antibody (Sigma) was used at a 1:100 dilution, and the
fluorescently labeled secondary antibodies described above were replaced with a
tyramide signal amplification kit (Molecular Probes), which was used according
to the manufacturer’s instructions. To quantify the extent of agonist-induced
ruffling in M1MR- and AT1AR-transfected Hep2 cells, 100 appropriately trans-
fected cells were counted and scored as ruffling or nonruffling. Cells on two
coverslips were counted per transfection, and the scoring was repeated on at least
three separate transfections.
Confocal images were taken at room temperature with a Bio-Rad MRC 1024
laser scanning confocal system with a Nikon Plan Apo 60 oil immersion lens
and an Optiphot 2 microscope equipped with Bio-Rad Lasersharp 2000 software
to acquire the images. Images were optimized for contrast in Adobe Photoshop,
but no further manipulations were made.
siRNA transfection. M2 and A7 cells (approximately 4  106 cells/dish) and
Hep2 cells (approximately 7  106 cells/dish) were transfected with siRNAs
directed against arr, FLNA, or control siRNA (20 g per 100-mm dish) by use
of Genesilencer as previously described (1) or by electroporation (for Hep2
cells). The siRNAs targeting arr or control siRNA have been described previ-
ously (1), and the siRNA sequence targeting FLNA is 5-GGGCTGACAACA
GTGTGGTGC-3, corresponding to base pairs 3074 to 3094 relative to the start
codon as previously described for use in an shRNA vector (36). All assays were
performed 72 h after siRNA transfection.
Purification of TAT-HA-FLNA(22-24) peptide. An overnight culture of
BL21(DE3)pLysS (Novagen) transformed with His6-TAT-HA-FLNA(22-24)
plasmid was diluted 1/20 and grown for 5 h at 37°C. Bacteria were resuspended
and lysed by sonication in 8 M urea, 20 mM HEPES, 100 mM NaCl, pH 8.0 (lysis
buffer). Insoluble material was eliminated by centrifugation at 17,000  g for 20
min, and the filtered supernatant was applied to a HiTrap chelating high-per-
formance column (Amersham Biosciences) loaded with 100 mM NiSO4. The
column was washed with lysis buffer, and bound protein was eluted with a 10 to
250 mM imidazole gradient in lysis buffer. Elution was monitored at a wave-
length of 254 nm. Fractions containing protein were collected, diluted with 2
volumes of 25% glycerol in PBS, and applied to a Sephadex G-25 column
preequilibrated with PBS-20% glycerol. The excluded fraction was characterized
by SDS-PAGE and Coomassie staining.
Preparation of GST-arr and in vitro binding assays. GST-arr1 or -arr2
fusion proteins were expressed in BL21(DE3)pLysS (Novagen) and purified on
a GSTrap fast-flow column (Amersham Biosciences) according to the manufac-
turer’s instructions. Products eluted with 10 mM glutathione were desalted on a
HiTrap desalting column (Amersham Biosciences) in PBS and characterized by
SDS-PAGE and Coomassie staining.
For in vitro binding assays, 25-g portions of GST fusion proteins were
immobilized on 20 l glutathione-Sepharose beads for 1 h at 4°C in PBS. Beads
were washed twice in 1 ml PBS and twice in binding buffer (50 mM Tris-HCl [pH
7.5], 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, supplemented with
protease inhibitors). Fifty g of TAT-HA-FLNA(22-24) was then added in a
final volume of 500 l of binding buffer. After 1 h at 4°C, beads were washed four
times with 1 ml of binding buffer. Complexes were applied on 10% SDS-PAGE
gels, and proteins were revealed by Ponceau red staining and Western blotting
with anti-HA 3F10 monoclonal antibody and anti-GST polyclonal antibody (gen-
erous gift of N. Varin, Institut Cochin, Paris, France).
RESULTS
Identification of FLNA as a arr-interacting protein. To
identify proteins interacting with arr, we made use of a cyto-
plasmic yeast two-hybrid system based on the membrane trans-
location of Sos called the SRS (4). The SRS uses cdc25H, a
strain of yeast which grows normally at 25°C but which harbors
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a thermosensitive mutation in the yeast Ras GEF Cdc25, abol-
ishing growth at 37°C. Membrane localization of hSos bypasses
the requirement for a functional yeast Ras GEF, Cdc25, permit-
ting growth at the restrictive temperature. Interaction between
two-hybrid proteins can result in hSos membrane localization.
For this method, the bait is fused to hSos, whereas the cDNA-
derived prey proteins are fused to a myristylation signal targeting
them to the membrane. Protein-protein interaction results in the
membrane translocation of hSos, allowing the yeast to grow at
37°C in the presence of galactose.
As full-length arr2 self-activated the SRS (Fig. 1a) we used
a C-terminally truncated form of arr2 (pSosGlyarr2C1)
containing amino acid residues 1 to 337 to screen a human
thymus cDNA library (Fig. 1b). Approximately 1.5  106 li-
brary colonies were screened, and 10 of the 135 positive clones
identified were found to encode the actin-binding protein
FLNA (Fig. 1c). The smallest partial clone obtained in the
SRS screen [pMyr-FLNA(22-24)] contained amino acids
2363 to 2647 of FLNA, corresponding to the majority of
repeat 22 through to its carboxy terminus (Fig. 1c). The
specificity of the interaction was confirmed by growth on
Leu/Ura/Trp plates containing galactose at 37°C follow-
ing retransformation of pMyr-FLNA(22-24) into
pSosGlyarr2C1-expressing cdc25H yeast (Fig. 1d).
To ascertain if FLNA could interact with full-length arr, we
used a classical two-hybrid system in L40 reporter yeast. Co-
transfection of FLNA(22-24) with arr1 or arr2 constructs
conferred the ability of yeast to grow on Leu/Trp/His
plates, whereas cotransfection of FLNA(22-24) or arr with
control vectors did not (Fig. 1e), indicating that both full-
length arr1 and arr2 are able to interact with FLNA. Con-
firming the findings obtained by the yeast two-hybrid system,
FIG. 1. Identification of FLNA as a arr-binding protein. (a) An adaptor coding for five glycine residues was inserted between the cDNAs for
hSos and full-length arr2 to reduce potential structural interference between the two proteins upon expression. When the pSosGlyarr2 chimera
(containing amino acids 1 to 410 of arr2) was introduced into cdc25H yeast in the absence of prey proteins, it promoted growth at 37°C, while
a control plasmid containing the SosGly fusion alone did not. This indicates that full-length arr2 on its own is capable of targeting Sos to the
membrane and is therefore not suitable as a bait. (b) To identify potential viable baits, a series of arr2 C-terminal truncations (containing amino
acids 1 to 316, 1 to 337, 1 to 359, 1 to 380, or 1 to 392) was cloned in frame to and downstream of the hSosGly coding sequence. Cdc25H yeast
cells were transformed with the truncations, incubated for 3 days, and subsequently replica plated and assessed for growth at 37°C. Growth at 37°C
of the truncations is indicated. arr2C1, a bait containing amino acids 1 to 337 and giving no background in yeast, was subsequently used to screen
the library. (c) Schematic representation of FLNA indicating the actin-binding domain (ABD), 24 repeat regions, and two hinge domains (H1 and
H2). The 10 partial FLNA clones identified in the SRS screen of a human thymus cDNA library are depicted as black bars. (d) Retransformation
of the smallest prey plasmid, pMyr-FLNA(22-24), containing amino acids 2363 to 2647 of FLNA, into pSosGlyarr2C1-containing cdc25H yeast.
Colonies that grew at 25°C following transformation were patched onto both galactose (prey expression-induced) and control glucose (prey
expression-repressed) Trp/Leu/Ura dropout plates. Growth at 37°C was assessed 2 or 3 days later. Yeast patches grew on galactose-containing
plates only at 37°C, confirming the interaction between arr2 and FLNA. (e) The L40 yeast reporter strain containing the indicated plasmids was
analyzed for histidine auxotrophy. Transformants were patched on selective medium with histidine (His) and then replica plated onto medium
lacking histidine (His) and incubated for 2 or 3 days. Growth in the absence of histidine indicates interaction between full-length arr1 and arr2
with FLNA(22-24). The Ras-Raf interaction was used as a positive control.
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arr2 containing a FLAG epitope tag coimmunoprecipitated
with Myc-tagged FLNA(22-24) from COS (Fig. 2a) and HeLa
cells (data not shown). Similarly, FLAG-epitope-tagged
FLNA(22-24) coimmunoprecipitated with arr1 (Fig. 2b) and
arr2 (data not shown) from COS cells. Endogenous full-
length FLNA also coimmunoprecipitated with FLAG-epitope-
tagged arr2 (Fig. 2c), and, finally, endogenous FLNA could
be coimmunoprecipitated with endogenous arr1 from Hep2
cells (Fig. 2d).
As coimmunoprecipitation experiments cannot rule out the
possibility that the interaction between FLNA and arr occurs
indirectly via other proteins, we performed pulldown ex-
periments using purified recombinant proteins. GST fusion
proteins of arr1 and arr2 were incubated with purified
His6-TAT-HA-FLNA(22-24). Complexes were isolated with glu-
tathione-Sepharose, subjected to SDS-PAGE, and transferred
to nitrocellulose. Ponceau red staining revealed that purified
FLNA(22-24) can interact directly with both arr1 and arr2
(Fig. 3). Binding was specific, as no FLNA(22-24) was detected
in the presence of GST alone. Taken together, these data
indicate that FLNA is a arr-binding protein and that the
interaction takes place via amino acids 2363 to 2647 of FLNA,
corresponding to the distal two-thirds of repeat 22 through to
its carboxy terminus.
FIG. 2. arr and FLNA associate in mammalian cells. (a) COS cells growing in 100-mm dishes were transfected with 1 g of C-terminally FLAG-tagged
arr2 (arr2-FLAG) or empty control vector with 1 g Myc-FLNA(22-24) containing amino acids 2363 to 2647 of FLNA or empty control vector. Immuno-
precipitations (IP) were performed as described in Materials and Methods. Immunoprecipitates were analyzed by SDS-PAGE and probed with polyclonal
anti-Myc antibody at a 1:1,000 dilution. Lysates of Myc-FLNA(22-24) represent 10% of the input used in the coimmunoprecipitation experiment. IB, Western
blotting. (b) COS cells were transfected with 1 g of FLAG-tagged FLNA(22-24) or empty control vector with or without 1 g of arr1 cDNA in pCMV5.
Immunoprecipitates were analyzed by SDS-PAGE and probed with anti-arr1-specific antiserum at a 1:1,000 dilution. Lysates ofarr1 represent 5% of the input
used in the coimmunoprecipitation experiment. (c) COS cells were transfected with 2 g of arr2-FLAG or empty control vector. Immunoprecipitates were
analyzed by SDS-PAGE and probed with an anti-FLNA antibody at a 1:1,000 dilution to detect endogenous full-length FLNA. Lysates of FLNA represent 5%
of the input used in the coimmunoprecipitation experiment. (d) Endogenous FLNA from Hep2 cell lysates was coimmunoprecipitated with endogenous arr
using anti-arr1 antibodies [arr(1178)]. Immunoprecipitates were analyzed as described above.
FIG. 3. Direct binding of arr to FLNA(22-24) in vitro. GST alone,
GST-arr1, or GST-arr2 bound to glutathione-Sepharose was incubated
with purified His6-TAT-HA-FLNA(22-24). Complexes were isolated and
washed as described in Materials and Methods. Ten percent of the His6-
TAT-HA-FLNA(22-24) peptide used in the pulldown experiments was
loaded as a control. After samples were resolved by SDS-PAGE, the gel was
transferred to nitrocellulose membrane and stained with Ponceau red solu-
tion. Positions of purified proteins are depicted. The identities of these pro-
teins were confirmed by immunoblot experiments using anti-HA and anti-
GST antibodies (not shown). GST-arr1 retained 21% 	 5% of the input,
and GST-arr2 retained 17% 	 2% (n 
 4).
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Mapping the binding domains of FLNA and arr. To fur-
ther refine the arr-binding region of FLNA within repeat
regions 22 to 24, we created a series of FLNA(22-24) trunca-
tions. Deletion either of repeat 24 or of repeat 24 and the
second hinge domain (H2) together had no effect on the bind-
ing of arr to FLNA in coimmunoprecipitation experiments
(Fig. 4a and b). Similarly, removal of amino acids 2363 to 2385
from repeat 22 of FLNA had no effect on arr-FLNA inter-
action (Fig. 4a and b). In contrast, the removal of all of repeat
22 resulted in the complete loss of the ability of arr to bind
FLNA (Fig. 4a and b). This indicates that amino acids 2386 to
2427 contained within repeat 22 of FLNA are essential for arr
binding. Similar results were obtained in yeast two-hybrid ex-
periments (data not shown). This region is located near the
regions of FLNA which interact with most FLNA-binding
GPCRs, encompassing repeat domains 14 to 21 or repeat 24
(5, 13, 20, 31, 39). Of particular interest with regard to MAPK
signaling is the fact that this region (residues 2386 to 2427 of
FLNA) is contained within previously identified binding sites
FIG. 4. Mapping of the interaction domains of arr and FLNA. (a)
Schematic representation of FLNA(22-24) truncations indicating in-
teraction with arr2. (b) arr2-FLAG was expressed with Myc-tagged
FLNA(22-24) truncation mutants as indicated. The amounts of the
various Myc-FLNA constructs contained in arr2-FLAG immunopre-
cipitates (IP) were assessed by Western blotting (IB) with an anti-Myc
antibody at a 1:1,000 dilution. (c) Schematic representation of
FLNA(22-24) alanine-scanning mutagenesis indicating interaction
with arr2. WT, wild type; Mut1 to Mut9, mutations 1 to 9. (d)
arr2-FLAG was expressed with Myc-tagged alanine-substituted mu-
tants of FLNA(22-24) (mutants 1 to 9) as indicated; the amounts of
Myc-tagged constructs contained in arr2-FLAG immunoprecipitates
were assessed by Western blotting. (e) Schematic representation of
wild-type (FL) and N- and C-terminal arr2 truncations (C and N,
respectively) indicating interaction with FLNA(22-24). (f) FLAG-
FLNA(22-24) or empty control vector was expressed with Myc-tagged
wild-type (FL) and N- and C-terminal arr2 truncations in COS cells.
The amounts of the various Myc-arr2 constructs contained in FLAG-
FLNA(22-24) immunoprecipitates were assessed by Western blotting.
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for the two FLNA-interacting MAP2K proteins, MEK1 (amino
acids 2282 to 2647) and MKK4 (amino acids 2282 to 2454)
(34). In an attempt to identify the specific residues contained
within amino acids 2386 to 2427 of FLNA that are responsible
for the binding of arr, a series of quintuple alanine-scanning
substitutions in this region were created in FLNA(22-24) and
tested for their abilities to bind arr in coimmunoprecipitation
experiments (Fig. 4c and d). The data demonstrate that several
successive substitutions severely impair or abolish the ability of
arr to interact with FLNA(22-24). These results therefore
indicate that multiple amino acid residues contained within the
2386 to 2420 FLNA region likely participate in arr binding.
To determine which region of arr is important for FLNA(22-
24) binding, coimmunoprecipitation experiments were carried
out using either the N-terminal part (amino acids 1 to 185, cor-
responding to the short N-terminal extremity and to the amino-
terminal globular domain) or the C terminal part (186 to 410,
corresponding to the carboxy-terminal globular domain and C-
terminal tail) of arr2 (Fig. 4e and f). FLNA(22-24) was actually
found to bind both domains of arr2, indicating the existence of
a complex interaction which involves the presence of multiple
binding sites on arr for FLNA. Similar data were obtained in
yeast two-hybrid experiments (data not shown).
FLNA(22-24) enhances GPCR-induced arr-mediated acti-
vation of ERK in COS cells. arr have recently been shown to
play an important role in MAPK signaling, functioning as scaf-
folds for GPCR-stimulated MAPK activation by binding com-
ponent kinases of the cascades, such as Raf-1 and ERK2.
Interestingly, FLNA has also been implicated in the regulation
of MAPK signaling with regard to the GPCR CaR (5, 20, 34)
and, as mentioned above, interacts with the MAP2Ks MKK4
and MEK1. The MEK1-binding site on FLNA overlaps the
arr-binding site identified here. Since the arr-MEK1 com-
plex may occur, at least in part, through indirect interaction
(33), we investigated whether the interaction between arr and
FLNA contributes to agonist-evoked GPCR activation of
ERK, looking at the effect of FLNA(22-24) overexpression on
arr-mediated ERK activation in COS cells. Overexpression of
FIG. 5. GPCR-induced arr-mediated activation of ERK is enhanced by FLNA(22-24). (a) Serum-starved COS cells transfected with plasmids
encoding HA-M1MR, GFP-ERK2, FLAG-arr1, or empty control vector and Myc-FLNA(22-24) or empty control vector were left untreated or
were stimulated with 100 M ACh for 5 min at 37°C. Cell lysates were resolved by SDS-PAGE, and phosphorylation of ERK2 was assessed by
immunoblotting (IB) using an anti-phospho-ERK1/2 antibody at a 1:1,000 dilution. Total GFP-ERK2, FLAG-arr1, and Myc-FLNA(22-24)
expression levels were confirmed by probing the immunoblots with anti-ERK1/2 (1:20,000 dilution), anti-FLAG (1:1,000 dilution), and anti-Myc
(1:1,000 dilution) antibodies, respectively. Gels were scanned, and phospho-ERK2 and total ERK2 levels were determined using NIH ImageJ. The
phospho-ERK2:total ERK2 ratio was calculated for receptor-stimulated cells expressing M1MR, arr1, and ERK2 (lane 4), and this value was
normalized to 100% ERK activation. The phospho-ERK2:total ERK2 ratio was subsequently calculated for ACh-stimulated cells expressing
M1MR, arr1, ERK2, and FLNA(22-24) (lane 6), which, when compared to cells expressing M1MR, arr1, and ERK2 (100%), gave a result of
148% 	 13%. The data represent the mean 	 SEM of four independent experiments (P  0.05). (b and c) Serum-starved COS cells transfected
with plasmids encoding HA-AT1AR (b) or AT1AR-DRY/AAY (c), GFP-ERK2, FLAG-arr1, or empty control vector and Myc-FLNA(22-24) or
empty control vector were left untreated or were stimulated with 1 M AngII for 5 min at 37°C. Cell lysates were resolved by SDS-PAGE, and
phospho-ERK2 and total ERK2 levels were assessed by immunoblotting as described for panel a. Expressions of FLAG-arr1 and Myc-FLNA(22-
24) were confirmed by immunoblotting as described for panel a (not shown). (d) Serum-starved COS cells transfected with plasmids encoding
HA-AT1AR, GFP-ERK2, FLAG-arr1, and either Myc-FLNA(22-24), Myc-FLNA(23-24), or empty control vector were left untreated or were
stimulated with 1 M AngII for 5 min at 37°C. Cell lysates were resolved by SDS-PAGE, and expressions of phospho-ERK2, total ERK2,
FLAG-arr1, Myc-FLNA(22-24), and Myc-FLNA(23-24) were assessed by immunoblotting as described for panel a.
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arr1 (Fig. 5a and b) or arr2 (data not shown) moderately
enhanced M1MR- and AT1AR-induced GFP-ERK2 phosphor-
ylation, as assessed by immunoblotting of COS cell lysates with
anti-phospho-ERK antibodies, in agreement with previous
findings (46). GFP-ERK2, which has been shown to behave
like wild-type ERK1/2 (46), was used in these experiments to
control for ERK phosphorylation in the transfected pool of
cells. When arr1 was overexpressed in combination with
FLNA(22-24), M1MR-induced ERK activation was signifi-
cantly potentiated (enhancement of 48% 	 13%; P  0.05
[n 
 4]) compared to stimulated control cells overexpressing
arr1 alone (Fig. 5a), indicating a role for FLNA in GPCR-
induced ERK activation. A similar potentiation was seen with
the AT1AR when arr1 was overexpressed with FLNA(22-24)
(Fig. 5b). As activation of ERK can occur via both G protein-
dependent and G protein-independent (i.e., arr-dependent)
mechanisms, we made use of a mutant AT1AR, which is mu-
tated in its DRY motif (DRY/AAY) and thereby rendered
severely impaired in Gq/11 coupling in COS cells (24), to
determine if the observed potentiation of ERK activation by
FLNA(22-24) mentioned above does indeed involve a arr-
dependent pathway. A number of recent studies indicate that
activation of ERK via this mutant receptor is completely inde-
pendent of G proteins and is exclusively mediated by arr (48,
2). AngII-induced activation of ERK via the DRY/AAY re-
ceptor was increased fourfold by arr1 and further enhanced
approximately twofold when arr1 and FLNA(22-24) were
both overexpressed (Fig. 5c). This finding confirms that the
increase in active ERK observed when FLNA(22-24) and
arr1 are both overexpressed is via a arr-dependent pathway
and not via a Gq/11-dependent pathway. Since FLNA(23-24)
did not coimmunoprecipitate with arr (Fig. 4), we anticipated
that this fragment would not potentiate arr-mediated activa-
tion of ERK as observed with FLNA(22-24). As expected,
AngII-induced activation of ERK via the AT1AR was poten-
tiated when arr1 was overexpressed with FLNA(22-24) but
not with FLNA(23-24) (Fig. 5d). This finding is consistent with
the hypothesis that the arr-binding site contained within
FLNA(22-24) contributes to the increased activation of ERK
when both proteins are overexpressed.
Taken together, the above results indicate that the interac-
tion of arr with FLNA may control the extent of GPCR-
induced arr-mediated ERK activation. As the carboxy termi-
nus of FLNA has been implicated in binding to MAPK cascade
components (see above), we tested whether FLNA(22-24) ex-
pression could increase the previously reported interaction
between arr and ERK2. The amount of GFP-ERK2 detected
in FLAG coimmunoprecipitates was markedly increased upon
coexpression of FLAG-arr1 with FLNA(22-24) (Fig. 6),
which is consistent with the idea that FLNA can facilitate the
formation of arr-ERK complexes.
FLNA is essential for full arr-mediated ERK activation
following M1MR activation. Since FLNA(22-24) potentiates
GPCR-mediated arr-dependent ERK activation, we investi-
gated whether this functional activity could be recapitulated by
the full-length protein. The specific effect of FLNA expression
on arr-mediated ERK activation was investigated by use of
FLNA-deficient M2 cells and their FLNA-replete counterpart,
A7 cells (Fig. 7), as a model. Both cell types contained equiv-
alent amounts of the MAPK signaling proteins arr, MEK1,
and ERK (Fig. 7a, left panels), and the distributions of arr in
both cell types were similar (Fig. 7a, right panels). This model
was used to confirm that maximal ERK activation requires
cooperation between arr and full-length FLNA. siRNA
against arr, recently employed to investigate the role of arr
in GPCR-induced ERK activation (1, 2, 48), was used to in-
hibit arr expression in both M2 and A7 cells. The siRNA
directed against arr led to an approximately 50% decrease in
endogenous arr levels in both M2 and A7 cells, as assessed by
Western blotting (Fig. 7b). In A7 cells transfected with the
M1MR and control siRNA oligonucleotides, a robust activa-
tion of ERK was observed following receptor activation (Fig.
7c, lanes 1 and 2). The siRNA-mediated reduction of arr in
A7 cells impaired M1MR-induced ERK activation by approx-
imately 30% (Fig. 7c, lanes 3 and 4). M2 cells transfected with
M1MR and control siRNA oligonucleotides demonstrated re-
duced receptor-activated levels of active ERK compared to A7
cells (Fig. 7c, lanes 6 and 2, respectively). In M2 cells with
reduced levels of arr following transfection with specific
siRNA, the induction of ERK was similar to that of cells
transfected with control oligonucleotides (Fig. 7c, lanes 8 and
6, respectively). Similar results were obtained using the
AT1AR (data not shown).
Finally, to confirm that the different levels of ERK activation
achieved in M1MR-transfected M2 and A7 cells were corre-
lated with the presence or absence of FLNA, full-length FLNA
cDNA was transiently transfected in M2 cells; this enhanced
ERK activation following M1MR stimulation (Fig. 7d). Taken
FIG. 6. FLNA(22-24) enhances arr-ERK2 association. COS cells
were transiently transfected with plasmids encoding GFP-ERK2,
FLAG-arr1, and Myc-FLNA(22-24) as indicated. FLAG immunopre-
cipitates were probed for coprecipitated ERK2. Equivalent expression
of constructs was confirmed by immunoblotting of cell lysates. The
histogram shows the amount of GFP-ERK2 detected in FLAG-arr1
immunoprecipitates. Data are normalized to 100% for cells expressing
arr and GFP-ERK2 and represent the mean 	 SEM of five indepen-
dent experiments (, P  0.02).
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together, these data indicate that to achieve full activation of
ERK via the M1MR in this model system, the simultaneous
expression of both FLNA and arr is essential.
Colocalization of arr, FLNA, and active ERK in membrane
ruffles in Hep2 cells following M1MR activation. FLNA is an
actin cross-linker that is appreciated as an important player in
actin remodeling. It is enriched in membrane ruffle structures,
which contain bundles of actin filaments that are more densely
packed than those of the underlying cell lamellae. arr have
recently been shown to be involved in GPCR-induced actin
cytoskeletal changes, which require arr-dependent MAPK
activation (16, 17, 23). If arr, FLNA, and active ERK do
cooperate to orchestrate receptor-mediated cell shape
changes, they would be expected to colocalize in areas of active
cytoskeletal remodeling following receptor activation. We
therefore extended our studies to Hep2 cells, which undergo
FIG. 7. Requirement of FLNA for M1MR-induced arr-mediated ERK activation. (a) M2 and A7 cells were lysed, and equivalent amounts of
proteins were subjected to SDS-PAGE and immunoblotted with the indicated antibodies (left panel) as described in Materials and Methods. M2 and A7
cells were grown and fixed on coverslips as described in Materials and Methods. Cells were then processed for fluorescence microscopy using A2CT
directed against arr and an anti-FLNA antibody and revealed by Alexa Fluor 594- or 647-conjugated antibodies (right panel). Scale bar, 5 m. (b)
Serum-starved M2 and A7 cells transfected with control (CTL) or arr siRNA oligonucleotides were lysed 72 h posttransfection, and equivalent amounts
of protein were subjected to SDS-PAGE and immunoblotted (IB) with the anti-arr antibody A2CT at a 1:5,000 dilution. (c) Serum-starved M2 and A7
cells transfected with a plasmid encoding HA-M1MR and either control or arr1/2 siRNA oligonucleotides were left untreated or were stimulated with
100 M ACh for 5 min at 37°C. Flow cytometry was performed with anti-HA antibodies on M2/A7 cells transfected with the HA-M1MR to determine
receptor density at the cell surface. Mean fluorescence intensity in A7 cells (n 
 3) was 3.76 	 0.35 times higher than that in M2 cells. A7 cells are
considerably larger than M2 cells, and the number of surface receptors/milligram protein was finally found to be equivalent between the cell types. Equal
receptor amounts of cell lysates (corresponding to equivalent protein levels) were resolved by SDS-PAGE, and phosphorylation of ERK1/2 was assessed
by immunoblotting using an anti-phospho-ERK1/2 antibody (1:1,000 dilution). Total ERK1/2 levels were controlled using an anti-ERK1/2 antibody
(1:20,000 dilution). Data shown represent the mean 	 SEM calculated from three independent experiments. The results in each experiment were
normalized to the level of ERK phosphorylation in stimulated A7 cells transfected with control siRNA. Significance was evaluated using a t test.
, P  0.02. NS, not significant. (d) Serum-starved M2 cells transfected with a plasmid encoding HA-M1MR and either pCMV-FLNA encoding
full-length FLNA (32) or a control plasmid were left untreated or were stimulated with 100 M for 5 min at 37°C. P-ERK1/2 and total ERK1/2
levels were assessed by immunoblotting as described for panel c. FLNA was detected using an anti-FLNA antibody (1:1,000 dilution).
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substantial membrane ruffling in response to various stimuli
(10). In Hep2 cells expressing M1MR, agonist treatment (ace-
tylcholine) for 5 min resulted in extensive cell shape change
with the rapid formation of membrane ruffles, a marker of
cytoskeletal reorganization (Fig. 8A, compare panels a [un-
stimulated control cells] and c). Actin was localized to these
membrane structures following receptor stimulation, as as-
sessed by phalloidin staining (Fig. 8A, compare panels b and
d). Under these conditions, 70% 	 0.8% (n 
 3) of the
M1MR-transfected cells formed ruffles (Fig. 9D). Similar re-
sults were obtained with the AT1AR (Fig. 8B, compare panels
a and b [unstimulated control cells] with c and d), with 68% 	
3.6% (n 
 3) of transfected cells demonstrating ruffling fol-
lowing angiotensin II stimulation (Fig. 9E). Interestingly, re-
ceptor, endogenous arr, and FLNA were colocalized in these
membrane ruffles following agonist stimulation, as shown in
Fig. 8C, panels a through d. As anticipated, active phosphory-
lated ERK was also found in ruffles following receptor activa-
tion (Fig. 8C, panels e through h). As FLNA(22-24), which
lacks the actin-binding domain, was found to potentiate ERK
activation (Fig. 5) like full-length FLNA, one would expect to
observe a colocalization of FLNA(22-24) with phosphorylated
ERK in membrane ruffles following receptor stimulation. As
shown in Fig. 8C, panels i through l, FLNA(22-24) was indeed
colocalized with activated receptor in the membrane ruffles of
Hep2 cells. To rule out potential artifactual colocalization of
proteins due to variations of cell thickness in the ruffling cells,
Hep2 cells were cotransfected with M1MR and YFP-tubulin as
a negative control. Activated M1MR, but not tubulin, was
concentrated in actin-rich ruffles (Fig. 8C, panels m through p).
This suggests that the observed enrichment of M1MR, arr, and
FLNA immunofluorescence in the membrane ruffles of agonist-
treated cells does indeed reflect true colocalization. In conclu-
sion, the GPCR-stimulated colocalization of arr, FLNA, and
P-ERK at membrane ruffles is consistent with a cooperative
role for arr- and FLNA-mediated ERK activation in this
GPCR-dependent process.
Essential requirement for arr, FLNA, and active ERK for
M1MR- and AT1AR-induced membrane ruffling in Hep2 cells.
To investigate the requirement for arr and FLNA in M1MR-
and AT1AR-induced ruffling in Hep2 cells, we employed siRNAs
to reduce the expression of endogenous levels of these pro-
teins. M1MR-transfected Hep2 cells showed a significant re-
duction in endogenous arr levels following siRNA cotrans-
fection (Fig. 9A, panel a) and exhibited a severely impaired
ruffling response. Only 18% 	 3.8% (n 
 3) of the M1MR-
and arr RNAi-cotransfected cells ruffled compared to cells
cotransfected with M1MR and control siRNA (Fig. 9A, com-
pare panels b and c with d and e and Fig. 9D). Similar results
were obtained by use of Hep2 cells cotransfected with the
AT1AR and arr RNAi, where, compared to their control
RNAi-transfected counterparts, only 20% 	 1.59% (n 
 3) of
the ruffling response was observed (Fig. 9E and data not
shown). Similarly, a reduction in FLNA levels by RNAi (Fig.
FIG. 8. M1MR, arr, FLNA, and active ERK colocalize in membrane ruffles in Hep2 cells following agonist stimulation. (A) Hep2 cells
transfected with HA-M1MR were left untreated or were stimulated with 100 M ACh for 5 min, fixed, processed for immunofluorescence with
an anti-HA (3F10) antibody, and revealed using an Alexa Fluor 488 antibody (a and c). Alexa Fluor 594 phalloidin was used to stain for actin (b
and d). (B) Hep2 cells transfected with HA-AT1AR were left untreated or were stimulated with 1 M AngII for 5 min, fixed, and processed for
immunofluorescence as described for panel A. (C) Hep2 cells transfected with HA-M1MR were stimulated with 100 M ACh for 5 min, fixed,
and processed for immunofluorescence using anti-HA (panels a and e), anti-arr (panels b and g), anti-FLNA (panel c), and anti-P-ERK1/2 (panel
f) antibodies. Hep2 cells cotransfected with HA-M1MR and Myc-FLNA(22-24) (panels i through l) or HA-M1MR and YFP-tubulin (panels m
through p) were stimulated with 100 M ACh for 5 min, fixed, and processed for immunofluorescence as described for panel A. Panel n shows
fluorescence emitted by YFP-tubulin. Scale bars, 5 m.
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9B, panel a) inhibited M1MR-induced membrane ruffling
compared to that of control RNAi-transfected cells (Fig. 9B,
compare panels d and e with b and c and Fig. 9D); the reduc-
tion was comparable to that observed in arr-depleted cells.
Essentially identical results were obtained using the AT1AR
receptor (Fig. 9E and data not shown). To further substantiate
the functional connection between the cooperative effect of
arr and FLNA on cytoskeletal rearrangement, on one hand,
and ERK activation, on the other hand, the direct involvement
of active ERK in ruffle formation was investigated in the same
FIG. 9. arr, FLNA and active ERK are all required to achieve full M1MR- and AT1AR-induced ruffle formation in Hep2 cells. (A) (a)
Representative blot showing Hep2 cells transfected with either control (CTL) or arr RNAi oligonucleotides. IB, immunoblotting. (b through e)
Hep2 cells transfected with HA-M1MR and either control or arr siRNA oligonucleotides were stimulated with 100 M ACh for 5 min, fixed, and
processed for immunofluorescence using an anti-HA (3F10) antibody (b and d) and Alexa Fluor 594 phalloidin to stain for actin (c and e). (B) (a)
Representative blot showing Hep2 cells transfected with either control or FLNA RNAi oligonucleotides. (b through e) Hep2 cells transfected with
HA-M1MR and either control or FLNA siRNA oligonucleotides were stimulated with 100 M ACh for 5 min, fixed, and processed for
immunofluorescence as described for panel A. (C) Hep2 cells cotransfected with HA-M1MR and MEK(K97A) were left untreated or were
stimulated with 100 M ACh for 5 min, fixed, and processed for immunofluorescence using anti-HA (3F10) and anti-MEK antibodies. (D) His-
togram showing the quantification from three independent experiments of ACh-induced membrane ruffling in Hep2 cells transfected with the
HA-M1MR and either control, arr1/2, or FLNA RNAi oligonucleotides or MEK(K97A) expression vector. Phalloidin staining was routinely used
for quantification, and approximately 100 appropriately transfected cells were scored as ruffling or nonruffling per experiment. The results shown
represent the means 	 standard errors of the means from three independent transfections. , P  0.001. Significance was evaluated using a t
test. (E) Histogram showing the quantification from three independent experiments of AngII-induced membrane ruffling in Hep2 cells transfected
with the HA-AT1AR and either CTL, arr1/2, or FLNA RNAi oligonucleotides or MEK(K97A) expression vector. Approximately 100 appro-
priately transfected cells were scored as ruffling or nonruffling per experiment. The results shown represent the mean	 standard error of the mean
from three independent transfections. , P 0.02; , P 0.001. Significance was evaluated using a t test. (F) Representative blot showing Hep2
cells transfected with either control or FLNA RNAi oligonucleotides. Immunoblotting was performed with anti-FLNA or anti-FLNB isoform-
specific antibodies (1:1,000 dilution; Chemicon). The blot demonstrates that the knockdown is specific for FLNA and does not affect FLNB. Scale
bars, 5 m.
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model system. Transfection of Hep2 cells with a plasmid en-
coding MEK1(K97A), a dominant negative mutant of MEK1
which interacts with ERK and inhibits its activation, reduced
M1MR-stimulated membrane ruffling to levels similar to those
observed for cells transfected with arr1/2 and FLNA siRNAs.
This finding indicates that active ERK is also required for
ruffle formation in these cells (Fig. 9C, panels c and d, and D).
Similar results were obtained with Hep2 cells cotransfected
with the AT1AR and MEK1(K97A) (Fig. 9E and data not
shown). Taken together, these results indicate an essential
requirement for arr, FLNA, and active ERK in M1MR- and
AT1AR-mediated cell shape change in our system, with the
selective inhibition of each component being sufficient to cause
a profound (60% or more) impairment of ruffle formation.
DISCUSSION
The studies described here indicate that the scaffolding and
actin-binding protein FLNA interacts with arr and support a
model where these two molecules cooperate to achieve full
GPCR- and arr-dependent activation of ERK. We also
present evidence to suggest that the extent and the subcellular
localization of the ERK activation, which is achieved through
this double scaffold, is capable of controlling cytoskeletal re-
arrangements such as the formation of membrane ruffles in
Hep2 cells.
The involvement of FLNA in ERK activation downstream of
an activated GPCR was documented for the CaR (5, 20), and
it was proposed that the functions of FLNA in this process
would be to stabilize the receptor at the plasma membrane and
to target signaling proteins to the receptor (50). Our data
indicate that arr, which interact with both FLNA- and ligand-
activated GPCRs, likely represent a third critical component of
the GPCR-FLNA signaling complex. In particular, genetic or
siRNA-mediated reduction of either arr or FLNA was found
to significantly impair M1MR-induced ERK activation. FLNA
has also been shown to have effects on ERK signaling for
receptors of other families, such as the insulin receptor (19). In
FLNA-deficient M2 cells, activation of ERK via the insulin
receptor is enhanced compared to that seen for FLNA-replete
A7 cells, and FLNA has thus been proposed to play a negative
role in ERK signaling via this receptor (19). Our findings on
M1MR-induced ERK activation in M2 and A7 cells are in
clear contrast to this result, with the divergent effects observed
upon FLNA depletion likely explicable by different mecha-
nisms used to activate ERK by GPCRs and the insulin receptor
in this cell model.
FLNA binds the MAP2Ks MEK1 (weak interaction) and
MKK4 (strong interaction) (34), which are upstream activators
of ERK and JNK, respectively. The minimal arr-binding site
on FLNA identified by deletion mapping and alanine-scanning
mutagenesis appears to be located between amino acids 2386
and 2420, contained within tandem repeat 22 of FLNA. Inter-
estingly, the arr-binding site is contained within the previ-
ously identified binding sites for MEK1 (amino acids 2282 to
2647; repeats 21 to 24) and MKK4 (amino acids 2282 to 2454;
repeats 22 to 23) (34). It is therefore tempting to speculate that
FLNA plays a positive role in arr-mediated ERK activation
by acting as a platform for the efficient recruitment of signaling
molecules involved in this signaling pathway in an example of
macromolecular cooperation. Indeed, the formation of signal-
ing complexes between MEK1, ERK, and arr appears to
depend, at least in part, on indirect interaction, as the overex-
pression of c-Raf1 increases the binding of both kinases to arr
(33). Accordingly, FLNA could perform a role similar to that
of c-Raf1 by promoting the formation of a stabler or more-
efficient arr-MAPK scaffold. Evidence in favor of this model
is provided by coimmunoprecipitation experiments that dem-
onstrate an increase in arr-associated ERK2 in the presence
of FLNA(22-24) and by the observation that full-length FLNA
or FLNA(22-24) can potentiate arr-mediated activation of
ERK. In addition, as full-length FLNA binds to cytoskeletal
elements at the periphery of the cytoplasm, including subcor-
tical actin, it would serve to localize and amplify the arr-
MAPK cascade within this cell compartment. Of interest is the
fact that arr2 can also bind to the MAP3K ASK1, to JNK3,
and indirectly, via JNK3, to the FLNA-binding MAP2K MKK4
to assemble an efficient JNK3 cascade (35). The role of FLNA
in the signaling of this arr2-MAPK scaffold therefore cer-
tainly merits further investigation. Finally, the functional sig-
nificance of the interaction between FLNA and arr is not
restricted to MAPK signaling only. During the preparation of
this work, it was reported that the dopamine D3 receptor,
FLNA, and arr form a basal ternary signaling complex (26).
Increases in GPCR kinase activity decreased the stability of the
complex, resulting in a reduction of D3R G protein-signaling
potential.
FLNA is enriched in membrane ruffles, which are subcellu-
lar compartments characterized by inhibited actin filament
turnover, a high level of other actin cross-linkers, such as ezrin,
and a high level of Rac activity (9). Membrane ruffles are
thought to arise following inefficient lamellipodium adhesion
and retraction towards the cell body. In Hep2 cells overex-
pressing the M1MR or AT1AR, short-term agonist stimulation
causes rapid membrane ruffling. Activated receptor, FLNA,
arr, and active ERK are localized to these ruffles. In this
study, we have demonstrated that knockdown of endogenous
FIG. 9—Continued.
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FLNA or arr levels inhibits M1MR- and AT1AR-induced ruf-
fling. Transfection of a dominant negative MEK [MEK1(K97A)],
which cannot activate ERK, also inhibits M1MR- and AT1AR-
induced ruffling. Taken together, these findings indicate that arr,
FLNA, and active ERK are functionally important in the forma-
tion of membrane ruffles in Hep2 cells following M1MR and
AT1AR stimulation.
Among the other FLN isoforms, FLNC has been reported to
be expressed predominantly in muscle, whereas FLNB was
found to be broadly distributed (43). FLNA knockdown with
specific siRNA did not change the level of FLNB expression in
Hep2 cells, as indicated by immunoblot studies with specific
antibodies (Fig. 9F). This observation is consistent with the
fact that the cooperation between arr and FLN is mostly
restricted to the FLNA isoform. Alternatively, the existence of
a marked difference in FLNA and FLNB concentrations in
Hep2 cells might explain why the specific reduction of FLNA
levels caused submaximal inhibition of membrane ruffling in
these cells.
Other GPCRs, such as protease-activated receptor-2 (16)
and fMLPR (8), induce membrane ruffling upon agonist acti-
vation. In the case of protease-activated receptor-2, the ruffling
response has been shown to be arr and ERK dependent (16)
whereas for the fMLPR, arr regulates ruffling via a Ral GDP
dissociation stimulator-RalA effector pathway (8). Lympho-
cytes derived from arr2-deficient mice have altered chemo-
tactic responses (14), and CXCR4- and AT1AR-mediated che-
motaxis in HEK cells occurs via arr2- and p38-dependent
signaling pathways (23, 44). These data together with our re-
sults indicate that following GPCR stimulation, arr play an
important role in regulating the actin cytoskeleton and subse-
quent cell shape change in processes such as cell motility. Our
results also suggest that FLNA could serve to localize arr-
mediated MAPK activation to specific cell compartments, pro-
viding a link between arr-mediated signaling events and cy-
toskeletal reorganization.
In addition to binding MAPK cascade components, repeat
regions 22 to 24 of FLNA are important in recruiting Rho
family GTPases and some regulatory cofactors implicated in
cytoskeletal regulation. The small GTPases Rho, Rac, and
Cdc42 bind FLNA repeats 22 to 24 constitutively, and RalA
binds repeat 24 in a GTP-dependent manner. Trio, a guanine
nucleotide exchange factor for Rho GTPases, binds FLNA via
repeats 23 and 24 (7), suggesting that switching Rho GTPases
bound to FLNA on and off may serve to regulate the spatial
positioning of actin assembly within the cell. This is of partic-
ular interest with regard to arr, as it was recently shown that
arr1 is involved in the activation of the small GTPase RhoA,
promoting stress fiber formation following AT1AR stimula-
tion (6).
To conclude, we have identified the actin binding and scaf-
folding molecule FLNA as a arr-binding partner, in agree-
ment with recently published data (26). arr and FLNA act
cooperatively to activate the MAPK ERK following GPCR
stimulation. In addition, arr, FLNA and active ERK play
obligate roles in cell shape change in Hep2 cells following
GPCR stimulation. We propose that FLNA integrates arr-
mediated signaling events and actin cytoskeleton regulation.
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